Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT03928743 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03928743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03928743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2019
Completion date
August 8, 2022
Enrollment
332 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis